Sep 15, 2026 8:00am EDT SCYNEXIS Appoints Todd Minga, M.D., as Senior Vice President, Research & Development
Sep 10, 2026 8:00am EDT SCYNEXIS Announces Appointment of Sanjay Subramanian as Chief Financial Officer
Aug 10, 2026 4:30pm EDT SCYNEXIS Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Jun 30, 2026 8:00am EDT SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
May 11, 2026 4:23pm EDT SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update
